Clinical trials: Drug
Headache, Migraine
Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females
A pharmacokinetic drug interaction study of erenumab and an oral contraceptive containing progestin and estrogen.
- Trial name
- NCT02792517
- Testing
- Erenumab, Ethynil Estradiol/Norgestimate Oral Contraceptive
- Where
- 4 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Amgen
Hyperlipidemia, Diabetes
Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness
The study was a 12-month, multi-centered, quasi-experimental design to assess point-of-care (POCT) screening/monitoring of subjects on antipsychotic agents for metabolic syndrome.
- Conditions
- Hyperlipidemia, Diabetes, Hypertension
- Trial name
- NCT02029989
- Testing
- Glucose and lipids, Glycosylated Hemoglobin A1c, Blood Pressure and Heart Rate
- Where
- United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
FSGS, MCD
Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
Adalimumab, a treatment which blocks tumor necrosis factor (TNF), was tested to see if it changed levels of urine biomarker levels, tissue inhibitor of metalloprotease-1 (TIMP1), and monocyte chemoattractant protein-1 (MCP1).
- Conditions
- FSGS, MCD, Focal Segmental Glomerulosclerosis, Minimal Change Disease
- Trial name
- NCT04009668
- Testing
- adalimumab
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Michigan
Advanced Solid Tumors
This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors
This is the first study using PF-03758309, an oral compound, in patients with advanced solid tumors. In this study different doses of PF-03758309 will be administered to different groups of patients.
- Trial name
- NCT00932126
- Testing
- PF-03758309
- Where
- 3 sites in United States, Australia
- Volunteers
- 35 people
- Sponsor
- Pfizer
Healthy Volunteer
A Study of TAK-951 in Healthy Adults
It is hoped that a medicine called TAK-951 will eventually be used to treat nausea and vomiting. Before then, the sponsor needs to understand how the body processes TAK-951 in healthy adults.
- Trial name
- NCT04486950
- Testing
- TAK-951
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Takeda
Intravenous Drug Usage, HIV/AIDS
Building on Needle Exchange to Optimize Prevention & Treatment
There are several biomedical interventions that can help people who inject drugs (particularly those with or at risk for HIV), but these services often do not get to the people most in need.
- Trial name
- NCT03567174
- Testing
- Integrated care van (ICV)
- Where
- United States
- Volunteers
- 720 people
- Sponsor
- Johns Hopkins University
Intervertebral Disc Degeneration
Duloxetine as an Analgesic Agent in Patients Undergoing Elective Spine Surgery
Duloxetine as an analgesic agent in patients undergoing elective spine surgery: evaluation with fentanyl demand controlled by the patient.
- Trial name
- Duloxetine (NCT02535000)
- Testing
- Duloxetine
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Serviço de Anestesiologia de Joinville
Knee Osteoarthritis, Knee Rheumatism
Does Adding an Additional Numbing Medication Injection in the Thigh Help With Pain Control After Knee Replacement Surgery?
One common anesthetic that is performed for total knee replacement surgery is spinal anesthesia with an adductor canal regional block, which involves injecting numbing medication in the thigh region for pain control after…
- Trial name
- NCT03326999
- Testing
- Obturator nerve regional block, Adductor canal regional block, Saline
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
HIV-1 Infection
Safety And Efficacy Of Rescriptor In Patients For Human Immunodeficiency Virus (HIV) Patients
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the Local Product Document (LPD) (unlisted adverse drug reaction), 2) the incidence of adverse drug reactions in this…
- Trial name
- NCT00823966
- Testing
- Rescriptor
- Volunteers
- 3 people
- Sponsor
- Pfizer
Ankylosing Spondylitis, Axial Spondyloarthritis
Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis
This is a 6-week randomized, double-blind trial of 4 different non-steroidal anti-inflammatory drugs in patients with axial spondyloarthritis to compare the change of pain score from baseline at 4 weeks to the change of pain…
- Trial name
- NCT03473665
- Testing
- Indomethacin, Diclofenac, Meloxicam
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Columbia University
HIV, AIDS
Care4Today v2.0 Application for Improving Adherence to HIV Medications
Although poor antiretroviral (ART) adherence in HIV does not mean a complete lack of therapeutic results, the benefit of ART increases as adherence improves.
- Trial name
- NCT02001064
- Testing
- Care4Today v2.0 mobile application + electronic monitoring of adherence
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of California, San Diego
Peripheral Artery Disease, Hypertension
Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure
This is a 26-week, prospective double-blind, randomized pilot trial of nebivolol versus an active control, metoprolol succinate, in patients with established lower-extremity peripheral artery disease, hypertension, and at least…
- Trial name
- ENCOMPASS (NCT01499134)
- Testing
- nebivolol, Metoprolol succinate
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Thomas Jefferson University
Pharmacogenetic Testing
Medication Optimization Using Pharmacogenetic Testing and the G-DIG to Reduce Polypharmacy in a Mental Health Population
Use of polypharmacy has significantly increased over the past two decades, which has unproven clinical benefit and is associate with an increased the risk of adverse side effects.
- Trial name
- MedOPT (NCT03468309)
- Testing
- Genecept Assay and G-DIG decision tool
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
Pharmacokinetics
A Drug-Food Interaction Study Between Colchicine and Grapefruit Juice
Grapefruit juice is an inhibitor of the cytochrome P450 (CYP) 3A4 enzyme system, one of the enzyme systems responsible for the metabolism of colchicine.
- Trial name
- NCT00984009
- Testing
- Colchicine, Grapefruit Juice
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Mutual Pharmaceutical Company, Inc.
Acute Coronary Syndrome
Study of LC23-1306 in Healthy Male Subjects
This will be a dose block-randomized, double-blind, active and placebo controlled, single and multiple dosing, dose-escalation study to evaluate tolerability, safety and pharmacokinetic/pharmacodynamic characteristics.
- Trial name
- NCT01526577
- Testing
- LC23-1306, Ticagrelor
- Where
- South Korea
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Advanced/Metastatic Neuroendocrine Tumors
Pazopanib as Single Agent in Advanced NETs
The incidence of new diagnosed patients with NET of the digestive tract including carcinoid and pancreatic islet cells tumors ranges from 2 to 10 per 100,000 in the western Countries (Kulke M, Mayer R.
- Trial name
- NCT01280201
- Testing
- Pazopanib
- Where
- 10 sites in Spain
- Volunteers
- 44 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Elderly
Six Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly
The purpose of the study is to evaluate the effect of a naturally occurring hormone, called Growth Hormone Releasing Hormone (GHRH), on the muscle, bone and fat tissues of the body.
- Trial name
- PP2 (NCT00807365)
- Testing
- GHRH
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Johns Hopkins University
Prediabetes, Obesity
Effects of Antidiabetic Medications on the Postprandial State in Prediabetes
This project addresses cardiovascular disease risk in patients with prediabetes. Levels of lipids after eating a meal ("postprandial lipids") are strong independent predictors of cardiovascular risk.
- Trial name
- NCT02104739
- Testing
- Exenatide, Saxagliptin, Exenatide extended-release (ER)
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Healthy
A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Abusers
The main purpose of this study is to determine if oxycodone and naltrexone combination capsules (ALO-02) have the potential to be abused.
- Trial name
- NCT01746901
- Testing
- intact ALO-02 60 mg/7.2 mg, crushed ALO-02 60 mg/7.2 mg, crushed oxycodone IR 60 mg
- Where
- Canada
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Pfizer
Chronic Hepatitis c, Cirrhosis, Liver
Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment
The HALT-C Trial is a National Institute of Diabetes and Digestive and Kidney Diseases sponsored, randomized clinical trial of long-term use of Peginterferon alfa-2a (pegylated interferon) in patients who failed to respond to…
- Conditions
- Chronic Hepatitis c, Cirrhosis, Liver, Fibrosis, Liver, Hepatic Cirrhosis
- Trial name
- HALT-C (NCT00006164)
- Testing
- Peginterferon alfa-2a + Ribavirin, Peginterferon alfa-2a
- Where
- 11 sites in United States
- Volunteers
- 1,050 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.